Thank you Lung-I Cheng for facilitating this robust discussion at Reuters Events Pharma about the value of #patient engagement in #cell and #gene therapy development.
Key takeaways included:
*Innovative study designs, such as leveraging #RWE, is needed to develop treatments for rare diseases which often have small patient populations.
*Leveraging information from #FDA's patient focused drug development meetings is important to understanding the patient experience.
*The rapid development of #CGTs is a paradigm shift for many regulating bodies, and risk-based flexability is needed to ensure timely #patient #access.
*Long-term patient follow up remains a challenge, but the value of capturing patient #data remains a priority.
Fellow Panelists:
Olga Granaturova, Co-founder, President, PriveBio
Jeffrey Meckler, Chief Executive Officer, Indaptus Therapeutics
Jason Lott, MD MSHP MHS FAAD, VP, Global Integrated Evidence Generation, Specialty Medicine, Integrated Care, and Cell-Gene Therapy, Bayer
Special thanks to my colleagues American Society of Gene & Cell Therapy for supporting my participation at events on this important topic.
#ASGCT #ASGCTadvocacy #CellTherapy #GeneTherapy
Produce & deliver innovation: It's now or never to partner with patients and develop value-based relationships with reimbursement stakeholders. Thank you all for such amazing panel discussion to wrap up our Cell & Gene Therapy track at Pharma USA 2024!
Lung-I Cheng, Jason Lott, MD MSHP MHS FAAD, Olga Granaturova,
Jeffrey Meckler and Margarita L. Valdez Martínez
#REpharmaUSA
Congratulations David R. Liu! Was great seeing you accept the award. So well deserved. You continue to amaze everyone with your brilliance, leadership and vision. Onwards and upwards 🚀